Back to Journals » Clinical Ophthalmology » Volume 12

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial

Authors Russo A, Scaroni N, Gambicorti E, Turano R, Morescalchi F, Costagliola C, Semeraro F

Received 12 December 2017

Accepted for publication 20 February 2018

Published 27 March 2018 Volume 2018:12 Pages 587—591

DOI https://doi.org/10.2147/OPTH.S159672

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser


Andrea Russo,1 Nicolò Scaroni,1 Elena Gambicorti,1 Raffaele Turano,1 Francesco Morescalchi,1 Ciro Costagliola,2 Francesco Semeraro1

1Eye Clinic, Department of Neurological and Vision Sciences, University of Brescia, Brescia, 2Eye Clinic, Department of Health Sciences, University of Molise, Campobasso, Italy

Purpose: The aim of this study was to evaluate whether indomethacin eye drops and intravitreal ranibizumab (IVR) injections would provide additional benefit over ranibizumab alone in the treatment of choroidal neovascularization (CNV).
Participants and methods: This was a randomized, prospective pilot study of eyes with new-onset CNV. Fifty-eight patients were randomized 1:1 into a ranibizumab monotherapy (RM) group and a ranibizumab plus indomethacin (RI) group. All patients received monthly 0.5 mg IVR injections for 3 months, followed by monthly injections administered as needed. RI group patients also self-administered one drop of 0.5% indomethacin three times a day for 12 months. All patients were followed up for 12 months.
Results: At 12 months, both groups showed significant improvement in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). The mean BCVA change from baseline to 12 months was -0.12±0.04 LogMAR and -0.20±0.04 LogMAR in the RM and RI groups, respectively, with the degree of change being significantly different between the two groups (P=0.04). At 12 months, the mean CRT in the RM group (316±41.2 µm) was significantly higher than that in the RI group (287±31.5 µm; P=0.004). The mean required number of IVR injections was 7.38±0.78 and 6.34±0.67 in the RM and RI groups, respectively (P<0.001).
Conclusion: Compared to IVR monotherapy, combination therapy with indomethacin eye drops and IVR provides superior anatomical and visual outcomes in patients with naive CNV lesions. Moreover, topical indomethacin might reduce the frequency of IVR injections, which is very beneficial considering the chronic and expensive nature of IVR therapy.

Keywords:
central retinal thickness, choroidal neovascularization, indomethacin, inflammation, ranibizumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]